Where is Interdict located?

Interdict is headquartered in San Francisco, United States.

Who is the current CEO of Interdict?

Larry Hamann of Interdict. They have also founded 1 company.

How many employees does Interdict have?

As of Apr 30, 2026, the latest employee count at Interdict is 11.

Is Interdict a funded company?

Interdict is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Interdict rank among its competitors?

Interdict ranks 8th amongst 9 active competitors, of which 3 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was TernaryTx, which secured an undisclosed amount in Feb, 2025.

Who are the top competitors of Interdict?

Interdict's top competitors include Avilar, Epsilico and iN Therapeutics. Among them, TernaryTx secured the most recent funding round in February, 2025.

Interdict - 2026 Company Profile, Team, Funding & Competitors

Interdict is a funded company based in San Francisco (United States), founded in 2022 by Larry Hamann. It operates as a Developer of a small molecule therapeutics platform to address undruggable targets. The company has 9 active competitors, including 3 that are funded. Its top competitors include companies like Avilar, Epsilico and iN Therapeutics.

Company Details

Developer of a small molecule therapeutics platform to address undruggable targets. The company's platform specializes in addressing historically undruggable targets in oncology, rare diseases, neurodegeneration and autoimmunity.

Website: www.interdictbio.com/
Email ID: *****@interdictbio.com

Key Metrics

Founded Year

2022

Location

San Francisco, United States

Stage

Funding Raised

Investors

Altitude Life Science Ventures

Ranked

8^th among 9 active competitors

Employee Count

11 as on Apr 30, 2026

Similar Companies

Avilar & 7 more

View Interdict's full profile

Interdict is a funded company. Interdict has 1 institutional investor.

View details of Interdict's funding rounds and investors

The founders of Interdict is Larry Hamann.

Here are the details of Interdict's key team members:

Larry Hamann: Co-founder, President and CEO of Interdict.

View details of Interdict's Founder profiles and Board Members

Interdict's employee count trend

Interdict has 11 employees as of Apr 26. Here is Interdict's employee count trend over the years:

Uncover Interdict's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Interdict include Avilar, Epsilico and iN Therapeutics. Here is the list of Top 10 competitors of Interdict, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Avilar 2020, Waltham (United States), Seed	Provider of drug discovery platform and protein degradation technology	$75.3M	Sanofi Ventures, Astellas Venture Management ... & 2 others	44/100
2nd	Epsilico 2020, Berlin (Germany), Seed	Generative AI technology for designing biologics	-	Life Science Valley, Picus Capital & 1 others	35/100
3rd	iN Therapeutics 2020, Yongin (South Korea), Funding Raised	Developer of drugs for patients with rare neurological diseases	-	Korea Omega Investment Corp, E&Venture Partners	31/100
4th	TernaryTx 2024, London (United Kingdom), Seed	Developer of computational platform for molecular glue discovery and design	-	Pace Ventures, i&i Bio	27/100
5th	Levitate Bio 2024, Kirkland (United States), Unfunded	Platform offering automated and customized AI solutions for biopharma drug discovery	-	-	26/100
6th	Ubiquitx 2021, Cambridge (United States), Funding Raised	Developer of AI-powered platform for targeted protein degradation therapeutics design	-	E14 Fund, HHS	22/100
7th	FuturedMe 2018, Tokyo (Japan), Funding Raised	Developer of platform for protein degradation for development of small molecule based drug	-	JAFCO Group	22/100
8th	Interdict 2022, San Francisco (United States), Funding Raised	Developer of a small molecule therapeutics platform to address undruggable targets	-	Altitude Life Science Ventures	25/100
9th	Adhesion Therapeutics 2024, Graz (Austria), Funding Raised	AI-enabled molecular glue degraders aimed at treating diseases	-	Europa	15/100